A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

NCT02011945 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Dasatinib
DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb